Retinal vascular occlusion affects the eye, specifically the retina. The retina is the light-sensitive layer of tissue that lines the back of your eye. It’s covered with special cells called rods and ...
An FDA target action date of August 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...
Panelists discuss how pivotal RVO trial data for aflibercept 8 mg show strong durability and visual outcomes while raising ...
COVID-19 infection may be boosting the numbers of a rare ocular condition in which vision is threatened when veins in the retina are blocked, eye specialists in Southern California report. Risk of ...
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...
Women filling a prescription for female hormone therapy (FHT), and presumably taking FHT, are not at increased risk of retinal artery or retinal vein occlusions. FHT, including oral contraceptive ...
Please provide your email address to receive an email when new articles are posted on . Women who filled a prescription for female hormone therapy did not have an increased risk for retinal vein ...
Patients with retinal vein occlusion who received Vabysmo experienced visual improvements as well as extended treatment intervals at 72 weeks, according to a study. At Angiogenesis, Exudation, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback